PURPOSE OF REVIEW: To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa). RECENT FINDINGS: Evidence from two randomized clinical trials (RCTs) and a meta-analysis show favorable toxicity profiles, and the potential to delay androgen-deprivation therapy (ADT) for up to two years in nearly half of patients with metachronous hormone-sensitive omPCa. Another RCT showed promising results of MDT as treatment-escalation method combined with androgen receptor signaling inhibitors (ARSI) in first-line treatment for castration-resistant omPCa.Surveys by radiation oncologists and consensus guidelines advocate for MDT across various omPCa scenarios. Multiple single-arm trials present encouraging results; however, the evidence for the benefit of MDT is still weak requiring further investigation to assess its impact on pivotal endpoints, such as survival and quality of life. SUMMARY: MDT is a promising approach in omPCa, and can be used to defer ADT in newly diagnosed metachronous omPCa patients, or to add to ARSI treatment at first diagnosis of castration-resistance. Ongoing prospective trials are needed to guide its optimal utilization in other settings, and patients should be informed about the evolving landscape of systemic therapies with proven survival benefits alongside MDT options.

Collegium Medicum Faculty of Medicine WSB University Dąbrowa Górnicza Poland

Department of Radiation Oncology University Medical Center Utrecht The Netherlands

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology Jikei University School of Medicine Tokyo Japan

Department of Urology San Giovanni Battista Hospital Città della Salute e della Scienza and University of Turin Turin Italy

Department of Urology University of Texas Southwestern Dallas Texas USA

Department of Urology Weill Cornell Medical College New York New York

Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Research Centre for Evidence Medicine Urology Department Tabriz University of Medical Sciences Tabriz Iran

Zobrazit více v PubMed

Phillips R, Shi WY, Deek M, et al. . Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 2020; 6:650–659. PubMed PMC

Ost P, Reynders D, Decaestecker K, et al. . Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018; 36:446–453. PubMed

Miszczyk M, Rajwa P, Yanagisawa T, et al. . The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies. Eur Urol 2024; 85:125–138. PubMed

Rogowski P, Trapp C, von Bestenbostel R, et al. . Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol 2022; 198:727–734. PubMed PMC

Guckenberger M, Lievens Y, Bouma AB, et al. . Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020; 21:e18–e28. PubMed

Zilli T, Achard V, Dal Pra A, et al. . Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol 2022; 176:199–207. PubMed

Nevens D, Jongen A, Kindts I, et al. . Completeness of reporting oligometastatic disease characteristics in the literature and influence on oligometastatic disease classification using the ESTRO/EORTC Nomenclature. Int J Radiat Oncol Biol Phys 2022; 114:587–595. PubMed

Francolini G, Gaetano Allegra A, Detti B, et al. . Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol 2023; 41:5561–5568. PubMed

Hao C, Ladbury C, Lyou Y, et al. . Long-term outcomes of patients on a phase ii prospective trial of oligometastatic hormone-sensitive prostate cancer treated with androgen deprivation and external beam radiation. Int J Radiat Oncol Biol Phys 2022; 114:705–710. PubMed

Reyes DK, Trock BJ, Tran PT, et al. . Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multimodal total eradication therapy in men with synchronous oligometastatic prostate cancer. Med Oncol 2022; 39:63. PubMed

Chang Y, Zhao X, Xiao Y, et al. . Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial. Front Med 2023; 17:231–239. PubMed

Deodato F, Pezzulla D, Cilla S, et al. . Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis. Clin Transl Oncol 2022; 24:1177–1183. PubMed

Kwan EM, Spain L, Anton A, et al. . Avelumab Combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the Phase 2 ICE-PAC Clinical Trial. Eur Urol 2022; 81:253–262. PubMed

Pan J, Wei Y, Zhang T, et al. . Stereotactic radiotherapy for lesions detected via 68Ga-prostate-specific membrane antigen and 18F-fluorodexyglucose positron emission tomography/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study. Eur Urol Oncol 2022; 5:420–427. PubMed

Dearnaley D, Hinder V, Hijab A, et al. . Observation versus screening spinal MRI and preemptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2022; 23:501–513. PubMed PMC

Deek MP, Van Der Eecken K, Sutera P, et al. . Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 2022; 40:3377–3382. PubMed PMC

Glicksman RM, Ramotar M, Metser U, et al. . Extended results and independent validation of a phase 2 trial of metastasis-directed therapy for molecularly defined oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys 2022; 114:693–704. PubMed

Hölscher T, Baumann M, Kotzerke J, et al. . Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive oligometastatic prostate cancer: the OLI-P Phase 2 Clinical Trial. Eur Urol Oncol 2022; 5:44–51. PubMed

Rajwa P, Yanagisawa T, Gruber M, et al. . Surgical metastasectomy for visceral and bone prostate cancer metastases: a mini-review. Eur Urol Focus 2023; 9:232–235. PubMed

Rajwa P, Robesti D, Chaloupka M, et al. . Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a Multicenter European Study. Eur Urol Oncol 2023. PubMed

Bianchi L, Ceci F, Balestrazzi E, et al. . PSMA-PET guided treatment in prostate cancer patients with oligorecurrent progression after previous salvage treatment. Cancers (Basel) 2023; 15:207. PubMed PMC

Mercier C, Claessens M, De Troyer B, et al. . Survival outcomes and pattern of relapse after SABR for oligometastatic prostate cancer. Front Oncol 2022; 12:863609. PubMed PMC

Pastorello E, Nicosia L, Cuccia F, et al. . PSMA-PET/CT-based stereotactic body radiotherapy (SBRT) in the treatment of uncomplicated non-spinal bone oligometastases from prostate cancer. Cancers (Basel) 2023; 15:2800. PubMed PMC